Navigation Links
Paragon Bioservices Awarded $4.99 Million U.S. Army Contract to Assist with Ebola Vaccine Development
Date:10/21/2010

BALTIMORE, Oct. 21 /PRNewswire/ -- Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that it has been awarded a $4.99 million contract to assist the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) in its vaccine development efforts.

The USAMRIID project involves process development and scale-up production of VLP-type vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses to support ongoing preclinical evaluation of efficacy, potency, and safety of these Filovirus vaccine candidates.  Utilizing their extensive VLP production and purification expertise, Paragon will develop a large-scale mammalian process suitable for future GMP manufacturing.

Ebola and Marburg viruses are a serious global health threat.  They cause hemorrhagic fever and have up to a 90 percent fatality rate in humans.  Currently, there are no vaccines or therapies available for these viruses.  They are commonly spread through blood and bodily fluids of infected patients who frequently succumb to hypovolemic shock.  Both viruses are potential agents of biological warfare or terrorism, since both are also infectious by aerosol.

Marco Chacon, Ph.D., CEO of Paragon Bioservices, commented, "As a scientist and a business man, it is extremely rewarding to be part of an effort that may improve public health, as well as enhance national preparedness.  Preventing the spread of Ebola and Marburg viruses is crucial to containing outbreaks and saving lives."

About Paragon BioservicesParagon Bioservices is a CMO focused on providing contract research, process development services and GMP manufacturing of biologics for Phase I/II clinical trials.  For more information about Paragon Bioservices, please visit www.paragonbioservices.com.

About USAMRIIDUSAMRIID, a division of the U.S. Army Medical Research and Materiel Command, plays a key role in both national defense and infectious disease research.  They are the lead medical research laboratory for the Department of Defense and the Biological Defense Research Program.  Their mission is essentially to conduct basic research on biological threats and to develop appropriate medical solutions—such as vaccines, drugs and diagnostics.Media Contacts:Tiberend Strategic Advisors, Inc.(212) 827-0020 Tamara Brighttbright@tiberendstrategicadvisors.comorClaire Sojdacsojda@tiberendstrategicadvisors.com
'/>"/>

SOURCE Paragon Bioservices
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Paragon Bioservices, Inc. Wins 2009 Lilly Global Supplier Award
2. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
3. ParagonRx Files with FDA REMS Panel Interim Analysis for Opioid Drugs Study
4. ParagonRx Sponsors Webinar-on-Demand By DSEC on Role of Drug Safety Officers
5. Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems
6. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
7. Avid Bioservices Expands Executive Team as it Prepares for Continued Growth
8. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
9. Dr. Yong Shi awarded NSF grant
10. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
11. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):